ATG induction therapy: Long-term effects on Th1 but not on Th2 responses

Transplant International

Volumn 18, Issue 2, 2005, Pages 226-236

  Weimer, Rolf ^a   Staak, Anne ^a   Süsal, Caner ^b   Streller, Sabine ^a   Yildiz, Sevgi ^a   Pelzl, Steffen ^b   Renner, Fabrice ^a   Dietrich, Hartmut ^a   Daniel, Volker ^b   Rainer, Lucy ^a   Kamali Ernst, Shirin ^c   Ernst, Wolfgang ^c   Padberg, Winfried ^a   Opelz, Gerhard ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Dialysis Centers Wetzlar and Langenselbold   (Germany)

Author keywords

Acute rejection; Adhesion molecules; Antithymocyte globulin; Cytokines; Kidney transplantation; Th1 Th2 response

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; THYMOCYTE ANTIBODY; CD30 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; CYTOKINE RECEPTOR; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; BLOOD CELL COUNT; CELL CULTURE; CELL STIMULATION; CELL TYPE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT SURVIVAL; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECIPIENT; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; GRAFT REJECTION; IMMUNOLOGY; IN VITRO STUDY; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; ANTIGENS, CD30; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; CELL ADHESION MOLECULES; CYTOKINES; FEMALE; GRAFT REJECTION; HUMANS; INFECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, CYTOKINE; TH1 CELLS; TH2 CELLS; TIME FACTORS;

EID: 20444448899     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.00047.x     Document Type: Article

References (34)

1. Yussim A, Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation - a prospective, randomized study. Transpl Int 2000; 13: 293.
2. Djamali A, Turc-Baron C, Portales P, et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation 2000; 69: 799.
3. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473.
4. Müller TF, Grebe SO, Neumann MC, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997; 64: 1432.
5. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514.
6. Opelz G, Schwarz V, Henderson R, Kneifel G, Ruhenstroth A. Non-Hodgkin's lymphoma after kidney or heart transplantation: frequency of occurrence during the first post-transplant year. Transpl Int 1994; 7: 353.
7. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769.
8. Randhawa P, Nalesnik M, Demetris J, Zeevi A. Interleukin-10 production by a B-cell line derived from human post-transplant lymphoproliferative disease. Hematol Oncol 1995; 13: 13.
9. Birkeland SA, Bendtzen K, Moller B, Hamilton-Dutoit S, Andersen HK. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999; 67: 876.
10. Nalesnik MA, Zeevi A, Randhawa PS, et al. Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clin Transplant 1999; 13: 39.
11. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993; 91: 2806.
12. Durandy A. Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future. Transpl Infect Dis 2001; 3: 104.
13. Süsal C, Pelzl S, Döhler B, Opelz G. Identification of highly responsive kidney transplant recipients using pre-transplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650.
14. Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Superior 3-year kidney graft function in patients with impaired pretransplant Th2 responses. Transpl Int 1998; 11: 350.
15. Merville P, Lambert C, Durand I, et al. High frequency of IL-10-secreting CD4+ graft-infiltrating T lymphocytes in promptly rejected kidney allografts. Transplantation 1995; 59: 1113.
16. Essner R, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857.
17. Lee MS, Wogensen L, Shizuru J, Oldstone MB, Sarvetnick N. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994; 93: 1332.
18. Qian S, Li W, Li Y, et al. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation 1996; 62: 1714.
19. Weimer R, Streller S, Staak A, et al. Effects of three immunosuppressive regimens on CD4 helper function, B cell/monocyte and cytokine responses in renal transplant recipients: 4 month follow-up of a prospective randomized study. Transpl Proc 2002; 34: 2377.
20. Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection. Transplantation 1996; 62: 1606.
21. Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2 and monokine responses. Human Immunol 2000; 61: 884.
22. Weimer R, Schweighoffer T, Schimpf K, Opelz G. Helper and suppressor T-cell function in HIV-infected hemophilia patients. Blood 1989; 74: 298.
23. Weimer R, Daniel V, Zimmermann R, Schimpf K, Opelz G. Autoantibodies against CD4 cells are associated with CD4 helper defects in human immunodeficiency virus-infected patients. Blood 1991; 77: 133.
24. Weimer R, Zipperle S, Daniel V, Pomer S, Staehler G, Opelz G. IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function. Transplantation 1994; 57: 54.
25. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997; 8: 1171.
26. Shield CF, Edwards EB, Davies DB, Daily OP. Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study. Transplantation 1997; 63: 1257.
27. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72: 1050.
28. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460.
29. Pelzl S, Opelz G, Daniel V, Wiesel M, Süsal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003; 75: 421.
30. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15: 435.
31. Hamann D, Roos MTL, van Lier RAW. Faces and phases of human CD8+ T-cell development. Immunol Today 1999; 20: 177.
32. Tomiyama H, Matsuda T, Takiguchi M. Differentiation of human CD8+ T cells from a memory to memory/effector phenotype. J Immunol 2002; 168: 5538.
33. Suresh M, Whitmire JK, Harrington LE, et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001; 167: 5565.
34. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transplant Immunol 2004; 12: 49.